Aspen is a salutary reminder that aspirant blue-chip companies don't necessarily need a long track record. CEO Stephen Saad led the acquisition of SA Druggists for R2,4bn in 1999, and confounded the sceptics by paying off a R1bn debt within five years. Now Aspen supplies 25% of the tablets or capsules in SA's public health-care system . But increased demand has meant pressure on capacity.
BDFM Publishers (Pty) Ltd disclaims all liability for any loss, damage, injury or expense however caused, arising from the use of, or reliance upon, in any manner, the information provided through this service and does not warrant the truth, accuracy or completeness of the information provided. The publisher's permission is required to reproduce the contents in any form including, capture into a database, website, intranet or extranet.
